These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29948743)

  • 1. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The history of pharmacovigilance.
    Caron J; Rochoy M; Gaboriau L; Gautier S
    Therapie; 2016 Apr; 71(2):129-34. PubMed ID: 27080830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical aspects of immunization and vaccine safety communication.
    Helfert SM
    Curr Drug Saf; 2015; 10(1):5-8. PubMed ID: 25859668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 9. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drugs for Use in Infants and Children: Where Are We Now, and Where Must We Go?
    Brown RE
    Anesth Analg; 2019 Oct; 129(4):1170-1174. PubMed ID: 30882517
    [No Abstract]   [Full Text] [Related]  

  • 13. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance.
    Yang CC; Yang H
    Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.